Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2011-02-23 Annual Report
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Annual Report 2010
Annual Report Classification · 100% confidence The document is titled 'Årsrapport 2010' (Annual Report 2010) and contains comprehensive financial statements, management commentary, audit information, and key performance indicators for the fiscal year 2010. Although it starts with a short announcement header (Selskabsmeddelelse nr. 3/2011), the document length and the inclusion of the full annual report content (as indicated by the table of contents and detailed financial tables) classify it as an Annual Report (10-K). FY 2010
2011-02-23 English
Report Publication Announcement 2011
Report Publication Announcement Classification · 99% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) from ALK dated February 14, 2011. The core content explicitly states the date and time when the 'årsrapport for 2010' (Annual Report for 2010) will be published (February 23, 2011) and announces an analyst/investor meeting ('analytikermøde') to discuss it. Since the document itself is an announcement about the future publication of the Annual Report and the associated meeting, and not the report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (2274 chars) is short, supporting the 'MENU VS MEAL' rule.
2011-02-14 English
Regulatory Filings 2011
Regulatory Filings
2011-02-14 Danish
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a press release dated 2011-01-28 announcing a significant exclusive license agreement between ALK and Torii Pharmaceutical Co., Ltd. regarding allergy immunotherapy products in Japan. It details financial terms (upfront payment, milestones, royalties), product scope (MITIZAX®, Alutard®), strategic rationale, and includes quotes from both CEOs. This type of announcement, detailing a major business transaction (licensing/partnership) and its financial implications, is characteristic of a corporate disclosure. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital change (CAP/SHA), it falls best under the category of a general corporate announcement or regulatory filing that doesn't fit elsewhere. Given the content is a major business development announcement, and it is not explicitly a report itself (like 10-K or IR), it is best classified as a Regulatory Filing (RNS) as a general disclosure, or potentially a Capital/Financing Update (CAP) if the focus was purely on the cash inflow, but the primary nature is a strategic partnership announcement. RNS is the most appropriate fallback for significant, non-standardized corporate news releases.
2011-01-28 Danish
Capital/Financing Update 2011
Capital/Financing Update Classification · 95% confidence The document describes an exclusive license agreement between ALK and Torii Pharmaceutical for the development and commercialization of allergy immunotherapy products in Japan. It details upfront payments, milestone payments, royalty structures, and R&D collaboration. This type of announcement, detailing a significant business transaction involving licensing, partnerships, or potential future revenue streams, most closely aligns with a Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS) if no other category fits. Since it involves a significant financial transaction (EUR 30 million upfront payment and future milestones) related to commercializing assets, it is best classified as a Capital/Financing Update (CAP), as it directly concerns the company's financial structure and future revenue generation through a major deal. It is not an earnings release (ER), an interim report (IR), or a full annual report (10-K).
2011-01-28 English
Regulatory Filings 2010
Regulatory Filings
2010-12-17 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.